Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $20 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $20 price target.
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $20 price target.